Semaglutide in Dermatology: 40-Slide CME Presentation Outline
I cannot generate actual PowerPoint slides, but I can provide you with a comprehensive 40-slide structure with detailed content that you can use to create your national CME presentation on semaglutide in dermatology.
SECTION 1: INTRODUCTION & BACKGROUND (Slides 1-8)
Slide 1: Title Slide
- Semaglutide and GLP-1 Receptor Agonists in Dermatology
- National CME Program
- [Your credentials and date]
Slide 2: Learning Objectives
- Understand GLP-1 receptor agonist mechanisms relevant to skin biology
- Recognize dermatologic applications and emerging evidence
- Identify cutaneous adverse effects and monitoring strategies
- Apply shared decision-making frameworks for patient selection
Slide 3: The GLP-1 Revolution
- FDA approval timeline: Liraglutide (2014), Semaglutide (2021) 1
- Originally for type 2 diabetes, now obesity and cardiovascular disease
- Expanding into dermatology through metabolic-inflammatory axis 2
- Weekly semaglutide 2.4 mg achieves 14.9% weight loss 1
Slide 4: Molecular Structure & Pharmacology
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 3
- Molecular weight: 4113.58 g/mol 3
- Albumin binding provides long half-life (~1 week) 3
- DPP-4 stabilization prevents degradation 3
- 89% bioavailability, dose-proportional exposure 3
Slide 5: Mechanism of Action - Metabolic Effects
- Glucose-dependent insulin secretion stimulation 3
- Glucagon suppression (8% fasting, 12% mean 24-hour) 3
- Delayed gastric emptying in early postprandial phase 3
- Appetite suppression via hypothalamic and brainstem nuclei 1
Slide 6: GLP-1 Receptors Beyond Metabolism
GLP-1 receptors are widely distributed in cutaneous tissues 2
- Keratinocytes, fibroblasts, immune cells 2
- Dermal white adipose tissue 4
- Microvascular endothelium 4
- Peripheral nerve endings (nociceptive modulation) 2
Slide 7: The Obesity-Inflammation-Skin Connection
- Obesity prevalence rising in U.S. and worldwide 2
- Systemic inflammation drives metabolic and dermatologic disease 2
- Psoriasis and hidradenitis suppurativa strongly associated with obesity 5
- Most eligible dermatology patients not receiving GLP-1RA therapy 5
Slide 8: Cardiovascular Benefits (Context for Patient Selection)
- LEADER trial: 13% reduction in cardiovascular death/MI/stroke with liraglutide 1
- SUSTAIN 6: 26% reduction with semaglutide (HR 0.74,95% CI 0.58-0.95) 1
- Benefits extend to non-diabetic patients with cardiovascular disease 1
- ADA/EASD recommend GLP-1RAs for high-risk patients independent of HbA1c 6
SECTION 2: IMMUNOMETABOLIC MECHANISMS IN SKIN (Slides 9-15)
Slide 9: Anti-Inflammatory Pathways
GLP-1RAs exert immunomodulatory effects by attenuating pro-inflammatory cytokine signaling 2
- Suppression of IL-23/Th17/IL-17 axis 7
- Modulation of NF-κB signaling 7
- Inflammasome pathway regulation 7
- Promotion of anti-inflammatory pathways 2
Slide 10: Intracellular Signaling Cascades
Multiple pathways modulated by GLP-1 signaling 7:
- cAMP/PKA: Primary signal transduction
- AMPK: Metabolic regulation and autophagy
- PI3K/Akt: Cell survival and proliferation
- NF-κB: Inflammatory gene transcription
Slide 11: Effects on Keratinocyte Function
- Enhanced keratinocyte migration in wound healing 4
- Modulation of proliferation and differentiation 7
- Cytoprotective mechanisms against oxidative stress 4
- Altered barrier function dynamics 4
Slide 12: Fibroblast and Collagen Effects
Bidirectional effects on dermal matrix 4:
- Positive: Enhanced fibroblast function in wound healing 4
- Negative: Decreased collagen synthesis with rapid weight loss 4
- Reduction in dermal white adipose tissue 4
- Clinical manifestation: facial volume loss ("Ozempic face") 8, 4
Slide 13: Microvascular and Perfusion Effects
- Improved microvascular perfusion 4
- Endothelial function enhancement 4
- Angiogenic support in wound healing 4
- Potential implications for chronic wounds 4
Slide 14: Immune Cell Modulation
GLP-1 receptors expressed on multiple immune cell types 2, 7:
- T lymphocytes (Th17 suppression)
- Macrophages (M1/M2 polarization)
- Dendritic cells (antigen presentation)
- Neutrophils (chemotaxis and activation)
Slide 15: Adipose Tissue Biology
- Preferential fat over lean mass loss 8
- Reduction in visceral adiposity
- Decreased adipose-derived inflammatory mediators
- Impact on subcutaneous facial fat compartments 4
SECTION 3: CLINICAL APPLICATIONS IN DERMATOLOGY (Slides 16-25)
Slide 16: Psoriasis - Mechanistic Rationale
Obesity is highly prevalent in psoriasis and worsens disease severity 5
- IL-23/Th17/IL-17 axis central to psoriasis pathogenesis 7
- GLP-1RAs suppress this inflammatory pathway 7
- Weight loss independently improves psoriasis outcomes
- Metabolic syndrome common comorbidity 2
Slide 17: Psoriasis - Clinical Evidence
- Observational data suggest improvement with GLP-1RA therapy 2
- Reduction in systemic inflammation markers 7
- Enhanced response to biologic therapies (theoretical)
- Caveat: No large randomized controlled trials yet 7
Slide 18: Hidradenitis Suppurativa - Mechanistic Rationale
HS strongly associated with obesity and metabolic dysfunction 5
- Inflammasome activation prominent in HS 7
- GLP-1RAs modulate inflammasome signaling 7
- Weight loss may reduce mechanical friction and occlusion
- Improved insulin sensitivity may reduce androgen-driven sebaceous activity
Slide 19: Hidradenitis Suppurativa - Clinical Evidence
Semaglutide significantly reduced HS activity over 24 months 9
- HASI-R score decreased from 11.34 ± 4.56 to 7.45 ± 3.21 9
- Improvements correlated with metabolic markers (p < 0.05) 9
- 110/120 participants completed follow-up (91.7%) 9
- Adverse events mild and transient (15.45%) 9
Slide 20: Acne - Mechanistic Rationale
- Insulin resistance increases androgen production
- Hyperinsulinemia stimulates sebaceous gland activity
- GLP-1RAs improve insulin sensitivity 9
- Potential direct effects on sebaceous glands 9
Slide 21: Acne - Clinical Evidence
Semaglutide reduced acne severity and sebaceous activity 9
- IGA score decreased from 1.92 ± 0.78 to 1.21 ± 0.63 over 24 months 9
- Sebaceous activity reduced from 186.45 ± 52.34 to 138.56 ± 42.78 µg/cm² 9
- Improvements independently correlated with metabolic enhancements 9
- Prospective observational study, 110 completers 9
Slide 22: Wound Healing - Mechanisms
GLP-1RAs may promote wound healing through multiple pathways 4:
- Modulation of inflammatory phase 4
- Enhanced keratinocyte migration 4
- Improved microvascular perfusion 4
- Fibroblast function support 4
- Antioxidant and cytoprotective effects 4
Slide 23: Wound Healing - Clinical Considerations
- Experimental data promising 4
- Clinical trials in dermatology lacking 4
- Potential benefit in diabetic ulcers (extrapolated from metabolic effects)
- Caveat: Nutritional deficiencies may impair healing 8
Slide 24: Atopic Dermatitis - Emerging Data
- Theoretical benefit through immunometabolic modulation 7
- Limited clinical evidence currently 7
- Potential role in obesity-associated AD
- Further research needed 7
Slide 25: Other Inflammatory Dermatoses
- Chronic urticaria (metabolic phenotype)
- Rosacea (potential vascular effects)
- Lichen planus (immune modulation)
- All require further investigation 7
SECTION 4: CUTANEOUS ADVERSE EFFECTS (Slides 26-32)
Slide 26: Overview of Dermatologic Adverse Events
Dermatologists must recognize the broad spectrum of cutaneous side effects 8:
- Alopecia
- Eczematous and hypersensitivity eruptions
- Bullous and pustular dermatoses
- Acneiform eruptions
- Hyperhidrosis
- Facial volume loss ("Ozempic face")
Slide 27: Alopecia
- Telogen effluvium most common pattern 8
- Typically occurs 3-6 months after initiation
- Related to rapid weight loss and nutritional deficiencies 8
- Usually self-limited with nutritional support
- Management: Nutritional assessment, supplementation, reassurance
Slide 28: Hypersensitivity Reactions
- Injection-site reactions common 10
- Eczematous eruptions reported 8
- Rare systemic hypersensitivity 8
- Management: Topical corticosteroids, antihistamines, consider discontinuation if severe
Slide 29: Bullous and Pustular Dermatoses
Rare but serious: autoimmune blistering disorders reported 8, 10
- Bullous pemphigoid cases documented
- Mechanism unclear (immune dysregulation vs. coincidence)
- Requires prompt recognition and dermatologic evaluation
- Management: Discontinue GLP-1RA, initiate immunosuppression as indicated
Slide 30: Facial Volume Loss ("Ozempic Face")
Rapid weight loss causes significant facial deflation and skin laxity 8, 4, 10
- Reduction in dermal white adipose tissue 4
- Decreased collagen synthesis 4
- Clinically resembles accelerated skin aging 4
- Major aesthetic concern for patients 8, 10
Slide 31: Managing "Ozempic Face"
Multidisciplinary approach essential 10:
- Prevention: Slower titration, nutritional optimization
- Counseling: Set realistic expectations before initiation 5
- Treatment options: Dermal fillers, biostimulators, skin tightening procedures
- Timing: Wait for weight stabilization before intervention 10
Slide 32: Other Cutaneous Effects
- Hyperhidrosis: Autonomic effects 8
- Acneiform eruptions: Rare, mechanism unclear 8
- Skin texture changes: Related to collagen alterations 4
- Monitoring: Document baseline appearance, serial photography
SECTION 5: SYSTEMIC ADVERSE EFFECTS RELEVANT TO DERMATOLOGY (Slides 33-36)
Slide 33: Gastrointestinal Effects
Most common adverse effects are GI-related 1:
- Nausea, vomiting, diarrhea dose-dependent 1
- More frequent with short-acting agents 1
- Slow titration improves tolerability 1
- Dermatology relevance: Malabsorption affects wound healing, may worsen alopecia
Slide 34: Nutritional Deficiencies
GI intolerance and reduced intake cause multiple deficiencies 8:
- Iron, vitamin B12, folate (anemia) 8
- Vitamin D, calcium (bone health)
- Protein malnutrition (lean mass loss) 8
- Impact: Impaired wound healing, hair loss, skin fragility
Slide 35: Perioperative Considerations
Delayed gastric emptying poses aspiration risk 1:
- Scintigraphy shows persistent delay even with chronic use 1
- Tachyphylaxis incomplete 1
- Increased residual gastric content at endoscopy (24.2% vs 5.1%, p=0.001) 1
- Recommendation: Discuss with anesthesia for dermatologic procedures requiring sedation
Slide 36: Other Systemic Effects
- Pancreatitis: Rare, use caution in history of pancreatitis 1
- Gallbladder disease: Monitor for symptoms 1
- Cardiac: Tachycardia (monitor if symptomatic) 1
- Ophthalmologic: Emerging concerns, refer as needed 8
SECTION 6: PATIENT SELECTION & SHARED DECISION-MAKING (Slides 37-40)
Slide 37: Who Should Be Considered?
Dermatologists should identify patients who may benefit 5:
- Psoriasis patients with BMI >30 or >27 with comorbidities 1
- HS patients with obesity and metabolic dysfunction 9
- Acne patients with insulin resistance and elevated sebaceous activity 9
- High cardiovascular risk (age ≥55, stenosis >50%, eGFR <60) 6
Slide 38: Contraindications and Precautions
Absolute contraindications 3:
- Personal/family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy (discontinue 2 months before planned conception) 3
Relative contraindications 1, 8:
Slide 39: Shared Decision-Making Framework
Use structured approach when discussing GLP-1RAs 5:
- Assess eligibility: BMI criteria, metabolic comorbidities, dermatologic severity
- Discuss benefits: Weight loss magnitude (14.9%), dermatologic improvement data, cardiovascular protection
- Review risks: GI intolerance, facial volume loss, alopecia, nutritional needs
- Set expectations: Slow titration, long-term commitment, aesthetic changes
- Plan monitoring: Nutritional labs, dermatologic follow-up, interdisciplinary coordination
Slide 40: Monitoring Strategy for Dermatologists
Practical monitoring approach 8, 5:
Baseline:
- Document weight, BMI, dermatologic severity scores
- Facial photography (aesthetic baseline)
- Nutritional labs: CBC, iron studies, B12, vitamin D
- Screen for contraindications
Follow-up (every 3-6 months):
- Dermatologic response assessment
- GI tolerability, nutritional intake
- Repeat labs if deficiency suspected
- Monitor for cutaneous adverse effects
- Coordinate with prescribing physician
Interdisciplinary collaboration:
- Primary care/endocrinology for prescription and metabolic monitoring
- Dietitian for nutritional optimization
- Ophthalmology if visual symptoms
- Dermatology for skin-specific management
Key Takeaways for Your Presentation
Bold your main messages:
- Semaglutide and other GLP-1RAs show promise for inflammatory dermatoses through immunometabolic mechanisms, with strongest evidence in HS and acne 9
- Dermatologists must recognize and manage cutaneous adverse effects, particularly facial volume loss and alopecia 8, 4
- Patient selection requires shared decision-making that balances metabolic benefits against aesthetic and systemic risks 5
- Multidisciplinary monitoring is essential, with dermatologists playing a key role in identifying candidates and managing cutaneous outcomes 8, 10
This structure provides comprehensive coverage suitable for a national CME program, with evidence-based content that can be adapted to your specific presentation format and time constraints.